清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

BCMA-Targeted Bortezomib Nanotherapy (BCMA-BTZ-Nps) Targets Tumor, Enhances Therapeutic Efficacy, Triggers Immunogenic Cell Death, Overcomes Drug Resistance, and Reduces Off-Target Toxicity in Multiple Myeloma (MM)

作者
Debasmita Dutta,Jiye Liu,Kenneth Wen,Keiji Kurata,Mariateresa Fulciniti,Annamaria Gullà,Teru Hideshima,Kenneth Carl Anderson
出处
期刊:Blood [Elsevier BV]
卷期号:142 (Supplement 1): 1934-1934 被引量:3
标识
DOI:10.1182/blood-2023-188237
摘要

Bortezomib (BTZ) is a standard-of-care treatment for multiple myeloma (MM). In addition to its direct anti-MM effects, we recently reported that BTZ triggers immunogenic cell death associated with improved outcome. However, adverse effects limit its long-term clinical use. To improve its therapeutic index, we encapsulated bortezomib in PEG-PLGA nanoparticles linked with antibodies that target B-cell maturation antigen (BCMA-BTZ-NPs) to specifically target MM cells. BCMA-BTZ-NPs showed significantly increased cellular internalization into wild-type (WT) H929 cells after 6h (99.2±0.7%) than non-targeted NPs (57.7±0.8%) (p<0.0001), with a time-dependent increase in internalization. Importantly, cellular internalization of the BCMA-BTZ-NPs in BCMA-KO H929 cells (15.9±2.5%) was significantly depleted (p<0.0001). BCMA-BTZ-NPs showed target-specific cytotoxicity against MM cell lines and primary tumor cells from MM patients. Furthermore, BCMA-BTZ-NPs induced cell death more efficiently than non-targeted nanoparticles or free BTZ, triggering potent mitochondrial depolarization assessed by JC1 staining in MM.1S (79.06±3.7% vs. 57.4±1.9% for BCMA-BTZ-NPs vs non-targeted NPs, p<0.01); and H929 cells (47.23±1.9% vs. 31.26±0.7% for BCMA-BTZ-NPs vs. non-targeted NPs, p<0.001). This was associated with enhanced activation of caspases 8, 9 and 3, followed by apoptosis. We also found that BCMA-BTZ-NPs were still effective in BTZ-resistant MM cell lines (36.66±1.8% residual chymotryptic activity in RPMI-Dox40 [resistant] and 40.29±1.0% in MM.1S [sensitive] cells), whereas free BTZ showed no inhibitory effect (100.01±4.6% residual chymotryptic activity in RPMI-Dox40), likely due to BCMA-BTZ-NPs entering the cell through receptor-mediated uptake which averts acquired BTZ resistance based on the drug pump P-glycoprotein (PgP). Importantly, BCMA-BTZ-NPs also enhanced immunogenic cell death (ICD) and activated the autophagic pathway more than free BTZ, evidenced by increased calreticulin cell surface exposure (free BTZ: 45.13±3.7% vs BCMA-BTZ-NP: 71.5±3.4%,) and induction of T-cell proliferation in both MM.1S (free BTZ: 36.5±2.6% vs. BCMA-BTZ-NP: 65.2±2.3%, p<0.001) and AMO-1 cells (free BTZ: 37.03±1.3% vs. BCMA-BTZ-NP: 66.33±3.3%, p<0.001). Of note, increased levels of TNFα, Granzyme B, and IFNγ were also present in BCMA-BTZ-NPs treated MM cells with DC (Dendritic cells) and T cells co-culture supernatants. Finally, we evaluated the in vivo target selectivity and therapeutic efficacy of BCMA-BTZ-NPs against human MM cells in a murine xenograft model. BCMA-BTZ-NPs selectively accumulated in the tumor more efficiently than non-targeted BTZ-NPs and were associated with more efficient tumor reduction and host survival. In summary, our study indicates that BCMA-BTZ nanotherapy accumulates at the tumor site, enhances therapeutic efficacy, triggers immunogenic cell death, overcomes drug resistance, and reduces off-target toxicity. These results provide the framework for clinical evaluation of BCMA-BTZ-NPs to increase the therapeutic index of BTZ and improve patient outcome in MM.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
cc发布了新的文献求助10
2秒前
4秒前
长孙烙完成签到 ,获得积分10
4秒前
菜鸟学习完成签到 ,获得积分10
11秒前
wayne完成签到 ,获得积分0
12秒前
junio完成签到 ,获得积分10
12秒前
威武的迎蓉完成签到,获得积分10
22秒前
慎独而已完成签到,获得积分10
25秒前
gzhy完成签到,获得积分10
30秒前
30秒前
科研通AI65的应助被RZH采纳,获得10
31秒前
充电宝的应助被慎独而已采纳,获得10
31秒前
馄饨炖饺子完成签到 ,获得积分10
33秒前
幸世完成签到 ,获得积分10
33秒前
浮生若梦发布了新的文献求助10
34秒前
沉静问芙完成签到,获得积分10
34秒前
淡淡的王大可完成签到 ,获得积分10
36秒前
犹豫的翠柏完成签到 ,获得积分10
37秒前
39秒前
辛夷完成签到,获得积分10
40秒前
慎独而已发布了新的文献求助10
44秒前
无忧的阳光完成签到 ,获得积分10
45秒前
我爱木棉完成签到 ,获得积分10
50秒前
Ava的应助被chun采纳,获得30
52秒前
在路上完成签到 ,获得积分10
53秒前
54秒前
1分钟前
聪慧天真完成签到,获得积分10
1分钟前
chichenglin完成签到 ,获得积分0
1分钟前
hy发布了新的文献求助10
1分钟前
hilufite完成签到,获得积分10
1分钟前
蚂蚁飞飞完成签到,获得积分10
1分钟前
syvshc的应助被初景采纳,获得10
1分钟前
研究所普朗克完成签到 ,获得积分10
1分钟前
Seagull完成签到,获得积分10
1分钟前
子车半烟完成签到,获得积分10
1分钟前
阿俊1212完成签到 ,获得积分10
1分钟前
谢谢你好心人完成签到 ,获得积分10
1分钟前
1分钟前
闪闪的访烟完成签到,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173230
求助须知:如何正确求助?哪些是违规求助? 9565593
关于积分的说明 21780525
捐赠科研通 7767429
什么是DOI,文献DOI怎么找? 3431542
关于科研通互助平台的介绍 2555764
邀请新用户注册赠送积分活动 2476697